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Abstract
Background: In this era of oxaliplatin-based adjuvant therapy, the optimal sequence in which chemoradiotherapy
should be administered for pathological stage N2 rectal cancer is unknown. The aim of this study was to
investigate this sequence.
Methods: In the primary adjuvant concurrent chemoradiotherapy (A-CRT) group (n = 71), postoperative concurrent
chemoradiotherapy was administered before adjuvant chemotherapy. In the primary adjuvant chemotherapy (A-CT)
group (n = 43), postoperative concurrent chemoradiotherapy was administered during or after adjuvant
chemotherapy. Postoperative radiotherapy comprised 45–50.4 Gy in 25–28 fractions. Concurrent chemotherapy
comprised two cycles of oral capecitabine (1,600 mg/m2) on days 1–14 and 22–35. Patients receiving adjuvant
chemotherapy with four or more cycles of XELOX (oxaliplatin plus capecitabine) or eight or more cycles of FOLFOX
(fluorouracil, leucovorin, and oxaliplatin) were included.
Results: Between June 2005 and December 2013, data for 114 qualified rectal cancer patients were analyzed. The
percentages of patients in whom treatment failed in the A-CRT and A-CT groups were 33.8% and 16.3%,
respectively (p = 0.042). More patients had distant metastases in the A-CRT group than in the A-CT group (32.4% vs.
14.3%, p = 0.028). Multivariate analysis indicated that the sequence in which chemoradiotherapy was administered
(A-CT vs. A-CRT) was an independent prognostic factor for both estimated disease-free survival [hazard ratio (HR) 0.
345, 95% confidence interval (CI) 0.137–0.868, p = 0.024] and estimated distant metastasis-free survival (HR 0.366,
95% CI 0.143–0.938, p = 0.036).
Conclusions: In pathological stage N2 rectal cancer patients, administering adjuvant chemotherapy before
chemoradiotherapy led to a lower rate of treatment failure, especially with respect to distant metastasis. Adjuvant
chemotherapy prescribed as early as possible might benefit this cohort of patients in this era of oxaliplatin-based
adjuvant therapy.
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Background
Since the pivotal German trial, preoperative chemoradio-
therapy following surgery has been preferred for locally
advanced rectal cancer in the routine practice of most in-
stitutions [1]. However, postoperative chemoradiotherapy
and adjuvant chemotherapy are still recommended for
patients with pathological stage II/III disease after defini-
tive surgery without preoperative chemoradiotherapy [2].
Among patients with pathological stage N2 rectal cancer
treated with curative intent, about 40% will have distant
metastases and 24% local recurrence at 5 years [3, 4]. Op-
timizing the combination of radiotherapy and chemother-
apy is therefore necessary to reduce recurrence. Trials
investigating patients with stage II/III rectal cancer indi-
cated that the sequence in which chemoradiotherapy was
administered was not associated with disease-free survival
(DFS), overall survival (OS) or relapse rate [5, 6]. However,
there are no reports focusing on pathological stage N2 pa-
tients. The ADORE trial and the CAO/ARO/AIO-04 trial
indicated the benefit of adjuvant oxaliplatin-based chemo-
therapy for rectal cancer [7, 8]. In view of the use of
leucovorin-modulated fluorouracil chemotherapy and the
inclusion of stage II rectal cancer in the previous studies
[5, 6], the aim of the present study was to evaluate the
sequence in which chemoradiotherapy should be adminis-
tered for pathological stage N2 rectal cancer in this era of
oxaliplatin-based adjuvant therapy.
Methods
Patients and patient workup
Treatment outcomes were analyzed for pathological stage
N2 rectal cancer patients after curative surgery and the ad-
ministration of differing sequences of adjuvant concurrent
chemoradiotherapy and chemotherapy. The inclusion cri-
teria were as follows: 1) postoperative (R0 resection) patho-
logical stage N2 rectal adenocarcinoma; 2) no evidence of
distant metastasis; 3) Karnofsky performance score ≥ 70; 4)
receiving postoperative capeciatbine based concurrent che-
moradiotherapy; 5) receiving adjuvant chemotherapy [four
or more cycles of XELOX (oxaliplatin plus capecitabine) or
eight or more cycles of FOLFOX (fluorouracil, leucovorin,
and oxaliplatin)]; 6) no neoadjuvant (chemo) radiotherapy;
7) no pregnancy or lactation; and 8) no previous malig-
nancy or other concomitant malignant disease.
In the primary adjuvant concurrent chemoradiotherapy
(A-CRT) group, postoperative concurrent chemoradiother-
apy was administered before adjuvant chemotherapy. In
the primary adjuvant chemotherapy (A-CT) group, postop-
erative concurrent chemoradiotherapy was administered
during or after adjuvant chemotherapy. The pretreatment
workup included a complete history and physical examin-
ation, liver and renal biochemical analysis, complete blood
cell count, electrocardiography, carcino-embryonic antigen
determination, abdominal ultrasonography and/or
computed tomography (CT), pelvic CT or magnetic reson-
ance imaging (MRI) and chest radiography. All patients
underwent disease staging using the American Joint Com-
mittee on Cancer 2010 staging system.
Treatment
Postoperative radiotherapy comprised 45–50.4 Gy (mini-
mum photon energy of 6 MV) in 25–28 fractions of 1.8 or
2.0 Gy five times per week over 5–5.5 weeks. This dose
was delivered using three-field conventional radiotherapy,
three-dimensional conformal radiotherapy or intensity-
modulated radiotherapy technique. The clinical target vol-
ume was delineated according to Roels’ guidelines [9], as in
previous studies [10–12]. Concurrent chemotherapy com-
prised two cycles of oral capecitabine (1,600 mg/m2) on
days 1–14 and 22–35. Perioperative therapy with XELOX,
FOLFOX4 or mFOLFOX6 for a total of 6 months is rec-
ommended for patients with stage N2 rectal cancer [2].
Follow-up
Follow-up included physical examination, liver and renal
biochemistry, complete blood count, and measurement
of tumor markers every 3 months for the first 2 years,
and every 6 months thereafter. Abdominal ultrasonog-
raphy and/or CT, pelvic CT or MRI and chest radiog-
raphy were performed every 6 months. Colonoscopic
examination was repeated annually. Treatment-induced
toxicities were scored according to the Common Ter-
minology Criteria for Adverse Events version 3.0.
Statistical analysis
SPSS version 22.0 (IBM, Armonk, NY, USA) was used
for statistical analysis. The OS, DFS, locoregional
recurrence-free survival (LRFS), and distant metastasis-
free survival (DMFS) were measured from the day of
surgery to the date of the event. Survival data were eval-
uated using the Kaplan–Meier method. The log-rank
test was used in univariate analysis to compare survival
outcomes between the A-CRT and A-CT groups. Multi-
variate analysis using a Cox proportional hazards model
was used to test independent significance by backward
elimination of insignificant explanatory variables. Host
factors (age and sex) were included as the covariates in
all tests. Chi-square, Fisher exact, and Mann–Whitney U
tests were used to compare differences between the two
groups. Statistical tests were based on a two-sided sig-
nificance level. p < 0.05 indicated statistical significance.
Results
Patient characteristics
Between June 2005 and December 2013, data for 114
rectal cancer patients who met all of the inclusion
criteria were analyzed retrospectively. Their clinical
characteristics are listed in Table 1. There were more
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patients with stage IIIc disease or tumor deposits in the
A-CT group (p < 0.05). Radiation dose did not differ be-
tween the two groups. However, 93% of patients in the
A-CRT group received a full dose of concurrent chemo-
therapy, compared with 86% of patients in the A-CT
group. The median intervals between surgery and the
start of adjuvant treatment in the A-CRT and A-CT
groups was 6.6 (range 3.6–14.0) weeks and 4.3 (1.9–
16.1) weeks, respectively (p < 0.001). In the A-CT group,
the median number of chemotherapy cycles adminis-
tered before radiotherapy was four (1–12).
Failure pattern
For all patients, the median local recurrence time was 26.2
(13.4–59.6) months and the median distant metastasis
time was 13.8 (6.5–50.0) months. The percentages of pa-
tients in whom treatment failed in the A-CRT and A-CT
groups were 33.8% and 16.3%, respectively (p = 0.042).
More patients had distant metastasis in the A-CRT group
than in the A-CT group (32.4% vs. 14.3%, p = 0.028). The
lung (n = 17) was the most common site of distant metas-
tasis, followed by the liver (n = 8), the bone (n = 4), non-
regional lymph nodes (n = 4), and the peritoneal seeding
(n = 3). Details of the patterns of recurrence are shown in
Table 2.
Survival
The median follow-up time was 34.1 (10.2–112.1) months.
For all patients, 3-year estimated OS, DFS, LRFS and
DMFS rates were 84.6%, 72.5%, 94.8% and 74.1%, respect-
ively. These rates were 81.8%, 66.7%, 93.7% and 67.5% for
patients in the A-CRT group and 90.8%, 83.9%, 97.4% and
86.6% for the A-CT group.
Univariate analysis suggested no statistically significant
difference in estimated DMFS rate between the A-CRT
group and the A-CT group; however, the 3-year esti-
mated DMFS in the A-CRT group was higher (86.6% vs.
67.5%, p = 0.074) (Fig. 1a). No statistically significant
Table 1 Clinical characteristics of 114 patients with pathological







Men 47 (66.2) 26 (60.5)




Distance from anal verge (cm) 0.773
≤ 5 cm 25 (35.2) 11 (25.6)
> 5 cm 46 (64.8) 32 (74.4)
Karnofsky Performance Score 0.464
≥ 90 36 (50.7) 25 (58.1)
<90 35 (49.3) 18 (41.9)
pT category 0.062
T2 4 (5.6) 3 (7.0)
T3 64 (90.1) 32 (74.4)
T4 3 (4.2) 8 (18.6)
TNM stage 0.049
IIIB 40 (56.3) 15 (34.9)
IIIC 31 (43.7) 28 (65.1)
Surgery 0.438
Low anterior resection 54 (76.1) 35 (81.4)
Abdominoperineal resection 17 (23.9) 7 (16.3)
Hartmann 0 (0.0) 1 (2.3)
Lymphovascular invasion 0.125
Yes 15 (21.1) 13 (30.2)
No 56 (78.9) 30 (69.8)
Tumor deposits 0.049
Yes 11 (15.5) 12 (27.9)
No 60 (84.5) 31 (72.1)
Number of nodes retrieved 0.080
Median 17 20
Range 6-51 8-41




≥ 45Gy 70 (93.6) 43 (100.0)
<45Gy 1 (1.4) 0 (0.0)
Concurrent chemotherapy 0.226
Full dose 66 (93.0) 37 (86.0)
Reduced dose 5 (7.0) 6 (14.0)
Time to adjuvant treatment (wk) <0.001
Table 1 Clinical characteristics of 114 patients with pathological
stage N2 rectal cancer (Continued)
Median 6.6 4.3
Range 3.6-14.0 1.9-16.1
Time to adjuvant radiotherapy (wk) <0.001
Median 6.6 17.1
Range 3.6-14.0 5.1-35.4





Abbreviations: A-CRT primary adjuvant concurrent chemoradiotherapy, A-CT
primary adjuvant chemotherapy
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difference was observed in estimated LRFS, DFS or OS
between the A-CRT and the A-CT groups (Fig. 1b, c, d).
Multivariate analysis was performed to adjust for vari-
ous prognostic factors. The following parameters were
included in the Cox proportional hazards model: age, gen-
der, distance from anal verge, lymphovascular invasion,
tumor deposits, number of nodes retrieved, number of
positive nodes, time to adjuvant treatment, TNM stage
and the sequence in which chemoradiotherapy was
administered (A-CT vs. A-CRT). The sequence of chemo-
radiotherapy was identified as an independent prognostic
factor for both estimated DFS [hazard ratio (HR) 0.345,
95% confidence interval (CI) 0.137–0.868, p = 0.024] and
estimated DMFS (HR 0.366, 95% CI 0.143–0.938, p =
0.036). The outcomes are shown in Tables 3 and 4.
Discussion
The findings of this study demonstrate lower treatment
failure and better survival (DFS and DMFS) rates when
adjuvant chemotherapy was administered first in patients
with pathological stage N2 rectal cancer.
With improvements in radiotherapy and surgery, re-
gardless of whether the patient receives preoperative or
postoperative chemoradiotherapy, the incidence of locore-
gional recurrence is relatively low; however, distant metas-
tasis has become the predominant problem, especially in
patients with stage N2 disease [3, 4]. New chemotherapy
regimens have been investigated to reduce the occurrence
of distant metastasis. The MOSAIC trial indicated that
adding oxaliplatin to fluorouracil-based adjuvant chemo-
therapy significantly improved 5-year DFS and 6-year OS
in stage II/III colon cancer, especially in stage III disease
[13]. Although the MOSAIC trial did not include rectal
cancer patients, oxaliplatin-based adjuvant chemotherapy
was still recommended for rectal cancer in the National
Table 2 Failure patterns of patients with pathological stage N2
rectal cancer in A-CRT group and A-CT group
Sites of recurrence A-CRT group A-CT group p
n % n %
Total no. of recurrence 24 33.8 7 16.3 0.042
No. of locoregional recurrence 4 5.6 1 2.3 0.647
No. of distant metastasis 23 32.4 6 14.3 0.028




Non-regional lymph nodes 3 1
Peritoneal seeding 2 1
Abbreviations: A-CRT primary adjuvant concurrent chemoradiotherapy, A-CT
primary adjuvant chemotherapy
Fig. 1 Kaplan–Meier curves of patients with pathological stage N2 rectal cancer treated with primary adjuvant concurrent chemoradiotherapy (A-CRT)
or primary adjuvant chemotherapy (A-CT). a The 3-year distant metastasis-free survival rates are 67.5% in the A-CRT group and 86.6% in the A-CT group
(p = 0.074). b The 3-year locoregional recurrence-free survival rates are 93.7% in the A-CRT group and 97.4% in the A-CT group (p = 0.629). c The 3-year
disease-free survival rates are 66.7% in the A-CRT group and 83.9% in the A-CT group (p = 0.153). d The overall survival rates are 81.8% in the A-CRT
group and 90.8% in the A-CT group (p = 0.378)
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Comprehensive Cancer Network guideline [2]. Despite no
head to head comparison in the adjuvant setting, current
treatment guidelines accept either XELOX or FOLFOX as
standard of care treatment options [2]. Randomized phase
III studies indicated that XELOX is noninferior to FOL-
FOX as a first-line treatment for metastatic colorectal
cancer [14, 15]. Most of the support for use of FOL-
FOX or XELOX as adjuvant chemotherapy in rectal
cancer is an extrapolation from the data available for
colon cancer [13, 16, 17]. The trial [18] investigating
the efficacy and safety of substituting fluorouracil
with capecitabine for perioperative treatment in lo-
cally advanced rectal cancer indicated that 5-year
overall survival in the capecitabine group was non-
inferior to that in the fluorouracil group. The authors
concluded that capecitabine could replace fluorouracil
in adjuvant chemoradiotherapy regimens for patients
with locally advanced rectal cancer.
In a meta-analysis of the optimal interval between sur-
gery and initiation of adjuvant chemotherapy in colorectal
cancer, a 4-week increase in the time to adjuvant chemo-
therapy was associated with a significant decrease in both
OS (HR 1.14, 95% CI, 1.10–1.17) and DFS (HR 1.14, 95%
CI, 1.10–1.18) [19]. Furthermore, in the study of Kusters
et al., adjuvant chemotherapy prevented local recurrence
in patients with locally advanced rectal cancer [20].
So far, there have been two trials in rectal cancer
evaluating treatment outcomes in relation to the se-
quence of adjuvant treatment [5, 6]. In a prospective
randomized trial, 308 patients with resected stage II/III
rectal cancer were randomly assigned to receive pelvic
irradiation at either the first or the third course of
leucovorin-modulated 5-fluorouracil chemotherapy [5].
In the preliminary results, a significantly higher DFS rate
was achieved in the early pelvic radiotherapy group (81%
vs. 70% at 4 years, p = 0.047) [21]. However, no signifi-
cant difference in DFS, OS or relapse rate was observed
between the two groups after a median follow-up period
of 121 months. In the study of Kim et al., 5-year treat-
ment outcomes were not significantly influenced by the
sequence of adjuvant treatment [6].
In the present study, we focused on stage N2 patients
who were more likely to develop distant metastases and
local recurrence. Only patients receiving adjuvant
chemotherapy (four or more cycles of XELOX or eight
or more cycles of FOLFOX) were included to ensure the
dose of adjuvant chemotherapy. More than 90% of
patients in both groups had received a full dose of radi-
ation, regardless of whether it was prescribed immedi-
ately after R0 resection or after adjuvant chemotherapy.
With oxaliplatin adjuvant chemotherapy, the whole
group exhibited high 3-year estimated OS, DFS, LRFS
and DMFS rates (84.6%, 72.5%, 94.8% and 74.1%,
respectively). Regarding the relationship between the
timing of adjuvant radio/chemoradiotherapy and local
recurrence, a systematic review indicated that the risk
of local recurrence increased with waiting time for
radiotherapy and the increase in local recurrence rate
may translate into reduced survival in some clinical
situations. However, patients with rectal cancer were
not included in this review [22]. In our study, the in-
cidence of locoregional recurrence was relatively low
in both the A-CRT and the A-CT groups (5.6% and
2.3%, respectively) regardless of whether concurrent
chemoradiotherapy was administered early or was
delayed. However, whether adjuvant chemotherapy is
given early or late does matter with regard to distant
metastasis and overall recurrence. After adjusting for
Table 3 Univariate analysis of prognostic factors for 114
patients with stage N2 rectal cancer
Item n 3y-OS 3y-DFS 3y-LRFS 3y-DMFS
% P % P % P % P
Sex
Men 73 86.0 0.983 75.1 0.831 95.3 0.980 73.9 0.970
Women 41 82.8 68.7 93.9 74.7
Age(years)
<60 91 86.5 0.533 71.1 0.280 95.2 0.943 73.0 0.321
≥ 60 23 75.5 75.2 92.3 75.2
Distance from anal verge (cm)
≤ 5 36 81.8 0.884 65.0 0.247 92.5 0.756 68.0 0.364
> 5 78 85.7 75.9 96.0 76.8
pT category
T2 7 100.0 0.223 68.6 0.908 100.0 0.744 68.6 0.892
T3 96 85.5 71.6 94.2 73.4
T4 11 60.6 85.7 100.0 85.7
TNM stage
IIIB 55 88.6 0.262 72.9 0.675 97.4 0.143 71.4 0.845
IIIC 59 81.2 72.2 92.3 76.8
Lymphovascular invasion
No 86 85.8 0.124 78.2 0.013 93.4 0.819 80.2 0.027
Yes 28 82.2 54.8 100.0 54.8
Tumor deposits
No 91 88.7 0.008 75.3 0.258 96.4 0.190 74.3 0.517
Yes 23 71.3 61.3 88.4 72.8
Number of nodes retrieved
<12 10 77.8 0.066 36.0 0.002 100.0 0.446 36.0 0.001
≥ 12 104 85.2 76.5 94.3 78.2
Sequence
A-CRT 71 81.8 0.379 66.7 0.153 93.7 0.629 67.5 0.074
A-CT 43 90.8 83.9 97.4 86.6
Abbreviations: OS overall survival, DFS disease-free survival, DMFS distant
metastasis-free survival, A-CRT primary adjuvant concurrent chemoradiother-
apy, A-CT primary adjuvant chemotherapy
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confounding factors with a Cox proportional hazards
model, we found that giving adjuvant chemotherapy
before concurrent chemoradiotherapy (A-CT vs. A-
CRT) was a favorable prognostic factor for estimated
DFS and DMFS. Given no significant difference in
locoregional recurrence between the A-CRT group
and the A-CT group in our study, we prefer to ad-
minister adjuvant chemotherapy before concurrent
chemoradiotherapy after definitive surgery in patho-
logical stage N2 rectal cancer patients.
There is a growing interest in developing neoadjuvant
chemotherapy for locally advanced rectal cancer. In a
phase 2, non-randomised trial of locally advanced rectal
cancer, 25 (38%, 27-51) of 65 achieved a pathological
complete response by adding 6 cycles of mFOLFOX6
between chemoradiation and surgery [23]. Recently, a
randomized phase 3 trial indicated perioperative mFOL-
FOX6 alone had inferior results and a lower pCR rate
than chemoradiotherapy but led to a similar downsta-
ging rate as fluorouracil-radiotherapy, with less toxicity
and fewer postoperative complications [24]. A phase 3
trial (NCT02533271) of comparing effectiveness of
short-term radiotherapy plus neoadjuvant chemotherapy
with preoperative long-term chemoradiotherapy in lo-
cally advanced rectal cancer is undergoing in our center.
There are several limitations to the present study,
including the retrospective nature of the study
design and the limited number of patients in the
two groups. Furthermore, we did not determine the
optimal time for intervention with radiotherapy. A
further prospective randomized study is necessary
for accurate evaluation of the sequence in which
chemoradiotherapy should be administered after pri-
mary surgery in patients with stage N2 rectal cancer.
However, conducting such a randomized controlled
trial will be difficult because, since publication of the
German trial, a larger number of patients with lo-
cally advanced rectal cancer have been treated with
preoperative chemoradiotherapy than with postopera-
tive chemoradiotherapy [1].
Conclusions
In pathological stage N2 rectal cancer patients, adminis-
tering adjuvant chemotherapy before chemoradiotherapy
led to a lower rate of treatment failure, especially with
respect to distant metastasis. Adjuvant chemotherapy pre-
scribed as early as possible might benefit this cohort of
patients in this era of oxaliplatin-based adjuvant therapy.
Abbreviations
A-CRT: Primary adjuvant concurrent chemoradiotherapy; A-CT: Primary
adjuvant chemotherapy; CI: Confidence interval; CT: Computed tomography;
DFS: Disease-free survival; DMFS: Distant metastasis-free survival;
FOLFOX: Fluorouracil, leucovorin, and oxaliplatin; HR: Hazard ratio;
LRFS: Locoregional recurrence-free survival; MRI: Magnetic resonance
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